NewAmsterdam Pharma Company N.V./$NAMS
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About NewAmsterdam Pharma Company N.V.
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments. The Company has one reportable segment, which comprises the discovery, development, and commercialization of transformative therapies for cardio-metabolic diseases.
Ticker
$NAMS
Sector
Primary listing
Employees
100
Headquarters
Website
NAMS Metrics
BasicAdvanced
$3.4B
-
-$1.72
0.07
-
Price and volume
Market cap
$3.4B
Beta
0.07
52-week high
$42.00
52-week low
$14.06
Average daily volume
792K
Financial strength
Current ratio
7.876
Quick ratio
7.686
Long term debt to equity
0.01
Total debt to equity
0.03
Profitability
EBITDA (TTM)
-225.463
Gross margin (TTM)
100.00%
Net profit margin (TTM)
-905.74%
Operating margin (TTM)
-1,002.90%
Revenue per employee (TTM)
$230,000
Management effectiveness
Return on assets (TTM)
-17.27%
Return on equity (TTM)
-28.29%
Valuation
Price to revenue (TTM)
156.931
Price to book
4.99
Price to tangible book (TTM)
4.99
Price to free cash flow (TTM)
-23.856
Free cash flow yield (TTM)
-4.19%
Free cash flow per share (TTM)
-1.25
Growth
Revenue change (TTM)
-50.61%
Earnings per share change (TTM)
-32.78%
3-year revenue growth (CAGR)
-39.71%
3-year earnings per share growth (CAGR)
12.98%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for NewAmsterdam Pharma Company N.V. stock?
NewAmsterdam Pharma Company N.V. (NAMS) has a market cap of $3.4B as of March 14, 2026.
What is the P/E ratio for NewAmsterdam Pharma Company N.V. stock?
The price to earnings (P/E) ratio for NewAmsterdam Pharma Company N.V. (NAMS) stock is 0 as of March 14, 2026.
Does NewAmsterdam Pharma Company N.V. stock pay dividends?
No, NewAmsterdam Pharma Company N.V. (NAMS) stock does not pay dividends to its shareholders as of March 14, 2026.
When is the next NewAmsterdam Pharma Company N.V. dividend payment date?
NewAmsterdam Pharma Company N.V. (NAMS) stock does not pay dividends to its shareholders.
What is the beta indicator for NewAmsterdam Pharma Company N.V.?
NewAmsterdam Pharma Company N.V. (NAMS) has a beta rating of 0.07. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.